Dedicator of cytokinesis protein 2 knockdown ameliorates LPS-induced acute lung injury by modulating Rac1/2 activity

Main Article Content

Yan Zhou
Wan Hu


acute lung injury, apoptosis, dedicator of cytokinesis protein 2, inflammation response, ras-related C3 botulinum toxin substrate 1/2


Dedicator of cytokinesis protein 2 (DOCK2) is a member of the cytoskeletal dynamics protein family, and is ubiquitously expressed in hematopoietic cells according to previous studies. This paper was intended to explore the underlying mechanism that DOCK2 might involve in the progression of acute lung injury (ALI). Following lipopolysaccharide (LPS) induction in the purchased A549 cells, the expression level of DOCK2 was determined and its knockdown was performed by transfection. Subsequently, the viability, inflammation, oxidative stress barrier, and apoptosis of transfected A549 cells were measured to observe the alterations. Inflammation-related and apoptosis-related proteins were measured by western blot analysis. Finally, 8-Chlorophenylthio-cyclic monophosphate (8-CPT), ras-related C3 botulinum toxin substrate (Rac) 1 agonist, was applied to treat cells for investigating the underlying mechanism regarding the role of DOCK2. According to the results, DOCK2 was upregulated in LPS-induced A549 cells. Following the knockdown of DOCK2, the release of inflammatory cytokines was alleviated, accompanied by attenuated oxidative stress, barrier injury, and apoptosis of LPS-induced A549 cells. Nonetheless, this trend was reversed by further treatment of 8-CPT. In summary, DOCK2 knockdown alleviates inflammation, oxidative stress, barrier injury, and apoptosis of LPS-induced A549 cells by associating with Rac1/Rac2. These findings highlighted the therapeutic potential of DOCK2 for the treatment of ALI.

Abstract 390 | PDF Downloads 343 HTML Downloads 140 XML Downloads 3


1. Quinlan GJ, Evans TW. Acute respiratory distress syndrome in adults. Hosp Med. 2000;61(8):561–563. 10.12968/hosp.2000.61.8.1400

2. McIntyre RC Jr., Pulido EJ, Bensard DD, Shames BD, Abraham E. Thirty years of clinical trials in acute respiratory distress syndrome. Crit Care Med. 2000;28(9):3314–3331. 10.1097/00003246-200009000-00034

3. Blank R, Napolitano LM. Epidemiology of ARDS and ALI. Crit Care Clin. 2011;27(3):439–458. 10.1016/j.ccc.2011.05.005

4. Pittet JF, Mackersie RC, Martin TR, Matthay MA. Biological markers of acute lung injury: Prognostic and pathogenetic significance. Am J Respir Crit Care Med. 1997;155(4):1187–1205. 10.1164/ajrccm.155.4.9105054

5. Reif K, Cyster J. The CDM protein DOCK2 in lymphocyte migration. Trends Cell Biol. 2002;12(8):368–373. 10.1016/S0962-8924(02)02330-9

6. Nishikimi A, Kukimoto-Niino M, Yokoyama S, Fukui Y. Immune regulatory functions of DOCK family proteins in health and disease. Exp Cell Res. 2013;319(15):2343–2349. 10.1016/j.yexcr.2013.07.024

7. Alosaimi MF, Shendi H, Beano A, Stafstrom K, El Hawary R, Meshaal S, et al. T-cell mitochondrial dysfunction and lymphopenia in DOCK2-deficient patients. J Allergy Clin Immunol. 2019;144(1):306–9 e2. 10.1016/j.jaci.2019.02.020

8. Yang L, Jing Y, Wang W, Ying W, Lin L, Chang J, et al. DOCK2 couples with LEF-1 to regulate B cell metabolism and memory response. Biochem Biophys Res Commun. 2020;529(2):296–302. 10.1016/j.bbrc.2020.05.152

9. Nishikimi A, Uruno T, Duan X, Cao Q, Okamura Y, Saitoh T, et al. Blockade of inflammatory responses by a small-molecule inhibitor of the Rac activator DOCK2. Chem Biol. 2012;19(4):488–497. 10.1016/j.chembiol.2012.03.008

10. Wang L, Zhang Y, Zhu G, Ma Y, Zuo H, Tian X. miR-16 exhibits protective function in LPS-treated cardiomyocytes by targeting DOCK2 to repress cell apoptosis and exert anti-inflammatory effect. Cell Biol Int. 2020;44(8):1760–1768. 10.1002/cbin.11371

11. Xu X, Zhu Q, Zhang R, Wang Y, Niu F, Wang W, et al. ITRAQ-based proteomics analysis of acute lung injury induced by oleic acid in mice. Cell Physiol Biochem. 2017;44(5):1949–1964. 10.1159/000485885

12. Terasawa M, Uruno T, Mori S, Kukimoto-Niino M, Nishikimi A, Sanematsu F, et al. Dimerization of DOCK2 is essential for DOCK2-mediated Rac activation and lymphocyte migration. PLoS One. 2012;7(9):e46277. 10.1371/journal.pone.0046277

13. Yao HY, Chen L, Xu C, Wang J, Chen J, Xie QM, et al. Inhibition of Rac activity alleviates lipopolysaccharide-induced acute pulmonary injury in mice. Biochim Biophys Acta. 2011;1810(7):666–674. 10.1016/j.bbagen.2011.03.020

14. Guo X, Chen SY. Dedicator of cytokinesis 2 in cell signaling regulation and disease development. J Cell Physiol. 2017;232(8):1931–1940. 10.1002/jcp.25512

15. Guo X, Li F, Xu Z, Yin A, Yin H, Li C, et al. DOCK2 deficiency mitigates HFD-induced obesity by reducing adipose tissue inflammation and increasing energy expenditure. J Lipid Res. 2017;58(9):1777–1784. 10.1194/jlr.M073049

16. Li S, Wei P, Zhang B, Chen K, Shi G, Zhang Z, et al. Apoptosis of lung cells regulated by mitochondrial signal pathway in crotonaldehyde-induced lung injury. Environ Toxicol. 2020;35(11):1260–1273. 10.1002/tox.22991

17. Fenteany G, Glogauer M. Cytoskeletal remodeling in leukocyte function. Curr Opin Hematol. 2004;11(1):15–24. 10.1097/00062752-200401000-00004

18. Nobes CD, Hall A. Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell. 1995;81 (1):53–62. 10.1016/0092-8674(95)90370-4

19. Sanui T, Inayoshi A, Noda M, Iwata E, Stein JV, Sasazuki T, et al. DOCK2 regulates Rac activation and cytoskeletal reorganization through interaction with ELMO1. Blood. 2003;102(8):2948–2950. 10.1182/blood-2003-01-0173

20. Ushijima M, Uruno T, Nishikimi A, Sanematsu F, Kamikaseda Y, Kunimura K, et al. The Rac activator DOCK2 mediates plasma cell differentiation and IgG antibody production. Front Immunol. 2018;9:243. 10.3389/fimmu.2018.00243

21. Zhai L, Liu M, Wang T, Zhang H, Li S, Guo Y. Picroside II protects the blood-brain barrier by inhibiting the oxidative signaling pathway in cerebral ischemia-reperfusion injury. PLoS One. 2017;12(4):e0174414. 10.1371/journal.pone.0174414

22. Kunimura K, Miki S, Takashima M, Suzuki JI. S-1-propenylcysteine improves TNF-α-induced vascular endothelial barrier dysfunction by suppressing the GEF-H1/RhoA/Rac pathway. Cell Commun Signaling. 2021;19(1):17. 10.1186/s12964-020-00692-w